Table 1.
patient characteristics
| Characteristics | No. (%) |
|---|---|
| Total | 2.429 (100) |
| Period | |
| 2004–2008 | 892 (36.7) |
| 2009–2013 | 1537 (63.3) |
| Age (mean/SD) | 66.9 (9.7) |
| Age group | |
| <65 | 881 (36.3) |
| 65 – 74 | 1000 (41.2) |
| 75 – 84 | 516 (21.2) |
| >=85 | 32 (1.3) |
| Sex | |
| Male | 1266 (52.1) |
| Female | 1163 (47.9) |
| Race | |
| White | 1912 (78.7) |
| Black | 497 (20.5) |
| Other | 20 (0.8) |
| Insurance | |
| Medicare only | 1207 (49.7) |
| Medicaid | 293 (12.1) |
| Commercial insurance/supplement | 835 (34.4) |
| Self-pay/no insurance | 94 (3.9) |
| Chest CT * | |
| Yes | 1,419 (92.3) |
| No/missing | 118 (7.7) |
| PET-CT* | |
| Yes | 1,223 (79.6) |
| No | 314 (20.4) |
| Invasive staging exam* | |
| Yes | 231 (15.0) |
| No | 1306 (85.0) |
| Pathologic T classification | |
| T1 | 1122 (46.2) |
| T2 | 949 (39.1) |
| T3 | 256 (10.5) |
| T4 | 88 (3.6) |
| Tx | 14 (0.6) |
| Pathologic N classification | |
| N0 | 1687 (69.5) |
| N1 | 316 (13.0) |
| N2 | 199 (8.2) |
| NX | 227 (9.3) |
| Pathologic stage | |
| I | 1581 (65.1) |
| II | 480 (19.8) |
| III | 316 (13) |
| IV | 39 (1.6) |
| Unknown | 13 (0.5) |
| Total Lymph nodes examined pre- and post-operative: median (IQR) | 6 (3, 11) |
| Number of mediastinal lymph nodes examined: median (IQR) | 2 (0, 5) |
| Number of mediastinal lymph node stations sampled: median (IQR) | 1 (0, 2) |
| Histology | |
| Adenocarcinoma | 1285 (52.9) |
| Squamous cell | 842 (34.7) |
| Adenosquamous | 68 (2.8) |
| Large cell | 111 (4.6) |
| Other | 123 (5.1) |
| Grade | |
| Well differentiated | 259 (10.7) |
| Moderately differentiated | 1037 (42.7) |
| Poorly differentiated | 732 (30.1) |
| Undifferentiated | 52 (2.1) |
| Not reported | 349 (14.4) |
| Extent of Resection | |
| Pneumonectomy | 192 (7.9) |
| Bilobectomy | 152 (6.3) |
| Lobectomy | 1782 (73.4) |
| Segmentectomy | 72 (3.0) |
| Wedge | 231 (9.5) |
| Surgical Technique | |
| Open | 1861 (76.7) |
| Robotically-assisted | 226 (9.3) |
| Video-assisted | 340 (14) |
| Surgical kit use (2011 – 2013) | |
| Yes | 233 (25.4) |
| No | 684 (74.6) |
| Postoperative chemotherapy* | |
| Yes | 235 (15.3) |
| No | 1297 (84.7) |
| Number of comorbidities* | |
| 0 | 319 (20.8) |
| 1 | 603 (39.2) |
| 2 | 376 (24.5) |
| 3 | 155 (10.1) |
| 4 + | 84 (5.5) |
| Mortality Rates | |
| 30 days | 109 (4.5) |
| 60 days | 163 (6.7) |
| 90 days | 203 (8.4) |
*
recent era (2009–2013); IQR=interquartile range